PanGenex Expands Clinical Trial Sites after Promising Pre-Clinical Data about Lower Coronary Arterial Calcium Scores in Cardiac

The Company initiated a 100 patient, placebo based, double blind
clinical trial at the CardioVascular Institute of the South. Early
results with only a handful of patients have encouraged the Company to
expand this trial.

The clinical trial involves a protocol to test its product Calci-CLEAR,
a two part system designed to cleanse and remove calcium deposits from
soft tissues such as veins and arteries. The study entails baseline
coronary arterial calcium (CAC) scans, bone mineral density scans (DXA),
and normal blood lipid and inflammatory markers. Under the protocol,
patients are screened and then placed on the product for a period of 5
months. Following the study duration, follow up CAC, DXA, and lab tests
are collected. Dr.
Peter Fail, the principle investigator for the trial, indicated that
one patient experienced a greater than 50% reduction in CAC score
following the 5 months of the study.

The results are not statistically significant due to the few completed
participants; however the outcome was significant enough to interest two
prominent cardiologists and advisory board members to the Company to
initiate trials at their respective clinics.

Steve Yakubov, Medical Director of the MidWest Cardiology Research
Foundation and Dr. Mark Turco, Cardiovascular Consultants, PA are both
preparing to initiate the clinical protocols at their sites.

"The data is slight, however, there is no other natural product
available to my knowledge that has this significant of an effect on CAC
scores...and to see these types of results is truly exciting." stated
PanGenex Director Dr. Ronald Caputo.

About PanGenex Corporation:

PanGenex
is a publicly traded corporation (PINK SHEETS: PGCX.PK) and
pursues business opportunities in the $70 billion nutraceutical and
dietary supplement industry. With a focus on the cardiovascular health
segment, PanGenex develops and markets sector leading, patented or
patent pending, condition specific nutraceutical and topical
over-the-counter (OTC) drugs and personal care products. Each product is
scientifically formulated to address specific health conditions. Many of
our products contain the purest grade of nutraceutical components
available anywhere without a prescription. PanGenex markets products
through healthcare practitioners, retail establishments and the internet
on websites such as www.PanGenex.com,
www.Calgenex.com
and www.HeartHealthyWorld.com.

Disclaimer:

CAUTIONARY STATEMENT ABOUT FORWARD-LOOKING STATEMENTS

This press release contains "forward-looking statements," which are
statements related to future, not past, events. In this context, the
forward-looking statements often include statements regarding our goals,
plans, projections and guidance regarding our financial position,
results of operations, market position, pending and potential future
acquisitions and business strategy, and often contain words such as
"expects," "anticipates," "intends," "plans," "believes," "seeks" or
"will." Any such forward-looking statements are not assurances of future
performance and involve risks and uncertainties that may cause results
to differ materially from those set forth in the statements. These risks
and uncertainties include, among other things: (a) general economic and
business conditions, (b) the level of strategic partner incentives, (c)
the future regulatory environment, (d) our cost of financing, (e) our
ability to complete acquisitions and dispositions and the risks
associated therewith, and (f) our ability to retain key personnel. These
factors, as well as additional factors, could affect our forward-looking
statements. We urge you to carefully consider this information. We
undertake no duty to update our forward-looking statements, including
our earnings outlook. The statements in this press release have not been
evaluated by the Food and Drug Administration. This product is not
intended to diagnose, treat, cure or prevent any disease.

SOURCE: PanGenex Corporation

Bulova Technologies Group, Inc. 
Beverly Mercer, 727-451-6560 
or 
PanGenex Corporation 
Mindy Rippeto, 813-623-5268 
investor@pangenex.com

For full details on (PGCX) PGCX. (PGCX) has Short Term PowerRatings at TradingMarkets. Details on (PGCX) Short Term PowerRatings is available at This Link.